



SpyGlass Pharma to Unveil Innovative Drug Delivery Platform for Chronic Eye Conditions at Eyecelerator Prior to the American Academy of Ophthalmology Meeting

September 15, 2022

SpyGlass Pharma, Inc.

"Drug Delivery – That Lasts" presentation introduces a new era of multi-year drug delivery to treat chronic ophthalmic diseases.

ALISO VIEJO, Calif., Sept. 15, 2022 /PRNewswire-PRWeb/ -- SpyGlass Pharma, a privately-held ophthalmic therapeutics company, today announced it will be unveiling a breakthrough drug delivery platform to treat chronic eye conditions at the Eyecelerator innovation meeting, being held prior to the American Academy of Ophthalmology (AAO) 2022 conference, September 29, in Chicago.

"After three years of groundbreaking work, we are delighted to unveil our breakthrough drug delivery platform that will enable all cataract surgeons to provide multi-year therapy to treat a chronic ophthalmic condition while patients undergo a common eye procedure," said Patrick Mooney, CEO of SpyGlass. "Notably, we have already begun developing a pipeline of potential drug products using this novel platform, and we are excited to share some initial program data with the ophthalmic community. The SpyGlass platform presents a new paradigm for the treatment of various chronic eye conditions, and its successful development could lead to better outcomes for both patients and physicians."

Details on SpyGlass' Eyecelerator 2022 Presentation:

Oral Presentation Title: "Drug Delivery – That Lasts"

Presentation Session: Pharma and Implants session

Presentation Time: 2:00 PM CDT/ 3:00 PM EDT

Presenting Speaker: Patrick Mooney, CEO

About SpyGlass Pharma

SpyGlass Pharma was co-founded by Dr. Malik Y. Kahook, MD and Glenn Sussman in 2019. The company is focused on the development of novel treatments for chronic ophthalmic diseases. The company's technology was originally developed in the Sue Anschutz-Rodgers Eye Center of the University of Colorado School of Medicine and is funded by [New Enterprise Associates](#) and [Vensana Capital](#). For more information please visit: <http://spyglasspharma.com>

Media Contact

Laurence Watts, Gilmartin Group, LLC., 1 619-916-7620, laurence@gilmartinir.com

Angela Salerno-Robin, dna Communications, 212-445-8219, ASalerno-Robin@dna-comms.com

SOURCE SpyGlass Pharma